Adicet bio announces oral presentation highlighting preclinical adi-270 data at the american society of gene and cell therapy (asgct) 28th annual meeting

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced the acceptance of an abstract for an oral presentation at the upcoming american society of gene & cell therapy (asgct) annual meeting taking place may 13-17, 2025, in new orleans, la. details of the oral presentation are as follows: title: adi-270, an armo.
ACET Ratings Summary
ACET Quant Ranking